Advertisement

FDA Approves Platelet-Receptor Antagonist Vorapaxar — Physician’s First Watch

Medical News |
May 12, 2014

FDA Approves Platelet-Receptor Antagonist Vorapaxar

By Larry Husten

The FDA has approved vorapaxar (Zontivity), an oral platelet-receptor antagonist, to reduce the risk for MI, stroke, cardiovascular death, and the need for revascularization in people with a history of MI or peripheral arterial disease.

The first in a new drug class known as protease-activated receptor-1 (PAR-1) antagonists, vorapaxar prevents platelet aggregation. However vorapaxar also increases bleeding risks — its principal side effect — and thus is contraindicated in those with a history of stroke, TIA, or intracranial bleeding.

In announcing the approval, the FDA said the drug lowered the risk for heart attack, stroke, and cardiovascular death in the target population from 9.5% to 7.9% over a 3-year period.

Adapted from CardioExchange

Reader Comments (4)

Matthew Tomcik MD Resident, Family Medicine/General Practice

As always, I assume this will take time to come into routine clinical use, but it is exciting to see a truly new class of medication in this field. I anticipate that further studies will be forthcoming.

Jaromir Gumulec MD Physician, Hematology, Faculty Hospital Ostrava, Czech Republic

Will be fora padat tested in patients with acute heparin-induced thrombocytopenia?

Pedro R. Jaunarena MD, FAAP Physician, Pediatric Subspecialty, Las Americas Pediatrics

I wonder if it has been used in Kawasaki patients allergic to aspirin?

Nematullah Fellow-In-Training, Cardiology, medanta the medicity

I welcome the new medication,hope does not have any black box of side effects.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement